701 E. Hampden Ave., Ste. 518
Englewood, CO 80113
1982 B.S. Yale College, Summa Cum Laude, Phi Beta Kappa
1988 M.D. Yale University School of Medicine
1988 Ph.D. Dept. of Pharmacology, Yale University School of Medicine
1988-1989 Internship, Internal Medicine Department, University of California – San Francisco
1989-1992 Residency, Neurology Department, University of California – San Francisco
1992-1995 Fellowship, Neurology Service, Massachusetts General Hospital and Harvard Medical School
1996-present University of Colorado, Neurology Dept, Aurora, CO
1996-1997 -Clinical Instructor
1997-2003 -Assistant Clinical Professor
2003-2012 -Associate Clinical Professor
2012-present -Clinical Professor
1997-2008 Rocky Mountain MS Center, Englewood, CO
1997-2008 -Director, Complementary and Alternative Medicine Program
1997-2002 -Associate Medical Director
2003-2007 -Medical Director
2009-present Colorado Neurological Institute (CNI)
2009-2014 -Medical Director, Multiple Sclerosis Program
2009-2014 -Medical Director, Complementary and Alternative Medicine Service
2014-present -Chair of Education
2014-present -Medical Advisory Committee
2014-present -Physician Associate
2006-2013 Editorial Board: Multiple Sclerosis Journal (formerly Multiple Sclerosis), Sage Publications
2007-2014 Member, Quality Standards Subcommittee of the American Academy of Neurology (AAN)
2009-2013 Advisor, Guthy-Jackson Charitable Foundation, San Diego, CA
2001-present Member, Healthcare Advisory Council, MS Association of America (MSAA)
2005-present Ad Hoc Grant Reviewer, National MS Society (NMSS)
2007-present Member, Committee for the Strauss-Wisneski Indigenous and Integrative Medicine Collection, University of Colorado
2012-present Grant Reviewer, Patient Management, Care, and Rehabilitation Pilot Review Committee, National MS Society (NMSS)
2012-present Member, Clinical Advisory Committee, Colorado-Wyoming Chapter of the National MS Society (NMSS)
1995-1997 Western Neurological Group, Denver, CO
1997-2007 Colorado Neurology, Englewood, CO
2007-present Neurology Care, address above
1993-present Board Certification, American Board of Psychiatry and Neurology
1995-present Medical License, Colorado Board of Medical Examiners
2016 Neuroscientist of the Year Award, awarded by Colorado Neurological Institute for groundbreaking visionary work in clinical care, research, and writing
2011 “Top 10 MS Books,” Complementary and Alternative Medicine and Multiple Sclerosis chosen by the Consortium of MS Centers (CMSC) as one of the top 10 lay books on MS
2000 Award for Best Presentation in Patient Education, annual meeting of the Consortium of Multiple Sclerosis Centers
1999 Labe Scheinberg Award, annual meeting of the Consortium of Multiple Sclerosis Centers
1988 American Epilepsy Society Award
1988 Medical Scientist Training Program Student
1987 Saul R. Korey Award in Experimental Neurology (American Academy of Neurology)
1982 Summa Cum Laude, Yale College
1982 Phi Beta Kappa, Yale College
1982 Fellows’ Prize, Yale College
1982 Distinction in Major, Yale College
1982 Scholar of the House, Yale College
1981 Bates’ Summer Travelling Fellowship, Yale College
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-modifying Treatment
A Prospective Observational Registry of H.P. Acthar Gel for the Treatment of Multiple Sclerosis Relapse.
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teiflunomide Treatment using Patient-Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients with Secondary Progressive Multiple Sclerosis
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-Over Study Evaluating Subject Ease-of-Use with Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) Treated with Rebif® 44mcg Subcutaneously Three Times a Week
Plegridy™ (peginterferon β-1a) Real World Effectiveness and Safety Observational Program
Botox® Treatment in Adult Patients with Upper Limb Spasticity
A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (dimethyl fumarate) Delayed-Release Capsules in Patients with Relapsing Forms of Multiple Sclerosis after Suboptimal response to Glatiramer Acetate
Teva Neuroscience, Protocol PM 028: A Randomized, Controlled, Open-Label Parallel Group Study to Evaluate the Effect of Regularly Scheduled Neutralizing Antibody Testing on Treatment Patterns vs Usual Care in High Dose Interferon-Treated Subjects, 2007-2010.
Teva Neuroscience, Protocol PM 024: Partnership Study: A Study of Adherence to Immunomodulating Agents with MS Center Support Services, 2006-2008.
Investigator-Initiated: Dietary Supplement Use Among People with Multiple Sclerosis, 2006-2009.
Investigator-Initiated: Injection Site Reactions Produced by the Immunomodulating Agents (IMAs) Used in the Treatment of Multiple Sclerosis, 2004-2007.
National MS Society, Project #9278: Comprehensive Evaluation of Multiple Sclerosis Adult Day Programs, 2005-2007.
Investigator-initiated: A Survey of Issues Related to Prayer and Spirituality Among a Large Group of People with MS, 2005-2007.
Investigator-Initiated: MS Patients and Marijuana Use Survey, 2004-2007.
Investigator-Initiated: Rocky Mountain MS Center Internet-Based Disease Registry and Database, 2003-2009.
Investigator-Initiated, National MS Society-supported: Rocky Mountain Multiple Sclerosis Center Tissue Bank, 2003-2009.
Investigator-Initiated: Survey Of Issues Related To Cognitive Dysfunction Among A Large Group Of People With Multiple Sclerosis, 2004-2006.
Teva Neuroscience, Protocol PM 07: A Multicenter, Randomized, Double-Blind Comparison of 3 Bevel versus 5 Bevel Needles, 2003-2005.
Teva Neuroscience: Outcomes Assessment Among Persons with RRMS who are Receiving Their Care at a Well-Established MS Center and Have used the Immunomodulating Therapies Long-Term, 2002-2004.
Investigator-Initiated: A Survey With Individualized Feedback Regarding Low Bone Mineral Density Among People With MS, 2001-2003.
Investigator-Initiated: A Survey Of Issues Related To Fatigue Among A Large Group Of People With MS, 2001-2003.
Investigator-Initiated: Efficacy, Safety, And Prevalence Of Acupuncture Use Among A Group Of People With MS, 2000-2002.
Investigator-Initiated: Effect of Donepezil on Cognitive Dysfunction in Multiple Sclerosis Patients, 2000-2003.
Teva Pharmaceuticals: PROMISE Trial (safety and efficacy of glatiramer acetate in patients with primary progressive MS), 1999-2002.
Biogen: Intravenous Antegren In Patients With MS During Exacerbation, 1998-1999.
ICOS: Hu23-F2G In MS Patients With Exacerbations, 1998-1999.